Low Th2 and high PD1+ TFh cells in blood predict remission after CTLA-4Ig treatment for 48 weeks in early rheumatoid arthritis
PLOS One · 2025
DOI: 10.1371/journal.pone.0330823 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2025. Verfasst von Tilia Selldén und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Inflammation Research, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Programmed Cell Death 1 Receptor, Th2 Cells, Abatacept. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VetenskapsrÃ¥det, Västra Götalandsregionen, IngaBritt och Arne Lundbergs Forskningsstiftelse.
Abstract (Originalsprache)
Objective
To determine whether baseline CD4 + T helper (Th) cell subset proportions in blood may serve as predictive biomarkers for achieving remission 48 weeks after initiating CTLA-4Ig, anti-tumor necrosis factor (TNF), or anti-interleukin 6 receptor (IL6R) treatment in patients with early rheumatoid arthritis (eRA).
Methods
This study included 60 untreated eRA patients from the larger randomized treatment trial NORD-STAR. They were treated with methotrexate (MTX) combined with either CTLA-4Ig (n = 17), anti-TNF (n = 22), or anti-IL6R (n = 21). Disease activity was assessed by clinical disease activity index (CDAI), C-reactive protein, and erythrocyte sedimentation rate. The primary outcome was remission (CDAI ≤ 2.8) at week 48, and the secondary outcomes were time to reach remission or sustained remission during the 48-week follow-up. CD4 + T cell subset proportions were analyzed fresh by flow cytometry at baseline and at 24 and 48 weeks.
Results
In CTLA-4Ig + MTX-treated patients, baseline Th2 together with PD1 + T follicular helper (TFh) cell proportions predicted CDAI remission at week 48 (AUC: 0.986, 95% CI 0.94–1.0). Survival analysis revealed that patients with Th2 proportions below 16.8% or PD1 + TFh proportions above 7.6% at baseline were more likely to achieve remission (log-rank p = 0.002 and p = 0.007, respectively), and sustained remission (log-rank p = 0.01 and p = 0.001, respectively), over the 48-week follow-up. CD4 + T cell subset proportions did not predict remission in patients treated with anti-TNF + MTX or anti-IL6R + MTX. Only CTLA-4Ig treatment reduced PD1 + TFh and PD1 neg TFh fractions after 48 weeks.
Conclusion
Circulating Th2 and PD1 + TFh cell proportions at baseline may serve as predictive biomarkers for achieving CDAI remission after 48 weeks of CTLA-4Ig treatment in eRA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Inflammation Research, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
- Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands.
- Department of Medicine, Rheumatology Unit, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden.
- Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Tilia Selldén, Kristina Lend, Michael T Nurmohamed, Bjorn Gudbjornsson
Förderung
- Vetenskapsrådet
- Västra Götalandsregionen
- IngaBritt och Arne Lundbergs Forskningsstiftelse
Zitieren
APA
Selldén, T., Andersson, K., Gjertsson, I., Hultgård Ekwall, A. K., Lend, K., Lund Hetland, M., Østergaard, M., Uhlig, T., Schrumpf Heiberg, M., Nurmohamed, M. T., Lampa, J., Sokka Isler, T., Nordström, D., Hørslev-Petersen, K., Gudbjornsson, B., Gröndal, G., van Vollenhoven, R., Maglio, C., Lundell, A. C., & Rudin, A. (2025). Low Th2 and high PD1+ TFh cells in blood predict remission after CTLA-4Ig treatment for 48 weeks in early rheumatoid arthritis. PLOS One. https://doi.org/10.1371/journal.pone.0330823
Vancouver
Selldén T, Andersson K, Gjertsson I, Hultgård Ekwall AK, Lend K, Lund Hetland M, et al. Low Th2 and high PD1+ TFh cells in blood predict remission after CTLA-4Ig treatment for 48 weeks in early rheumatoid arthritis. PLOS One. 2025. doi:10.1371/journal.pone.0330823
BibTeX
@article{Selldn2025,
author = {Selldén, Tilia and Andersson, Kerstin and Gjertsson, Inger and Hultgård Ekwall, Anna-Karin and Lend, Kristina and Lund Hetland, Merete and Østergaard, Mikkel and Uhlig, Tillmann and Schrumpf Heiberg, Marte and Nurmohamed, Michael T and Lampa, Jon and Sokka Isler, Tuulikki and Nordström, Dan and Hørslev-Petersen, Kim and Gudbjornsson, Bjorn and Gröndal, Gerdur and van Vollenhoven, Ronald and Maglio, Cristina and Lundell, Anna-Carin and Rudin, Anna},
title = {Low Th2 and high PD1+ TFh cells in blood predict remission after CTLA-4Ig treatment for 48 weeks in early rheumatoid arthritis},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0330823}
}
EUVIMED